Pharvaris says Lancet study met all endpoints
Pharvaris said its phase 3 RAPIDe-3 study of deucrictibant IR in hereditary angioedema met its primary endpoint and all 11 secondary endpoints. The company also said the drug was under FDA and EMA review.